Our Research

Our Research

>> Research Departments
>> Find Clinical Trials
>> Our Publications
>> Our Research Collaborations


Contact Details

  Street address:
Level 11, KGV Building
Missenden Road
CAMPERDOWN NSW 2050
 
Postal address:
Post Office Box M30
Missenden Road NSW 2050

Phone: (02) 9515-6111
Fax: (02) 9515-9610

Online Feedback

Tissue Pathology and Diagnostic Oncology

Our Research

Molecular oncology:
Developing new approaches to diagnosing and predicting the behaviour of a range of cancers, including melanoma, lung and breast cancer, as well as predictive markers for targeted therapies.

Melanoma:
Studying risk, causes, diagnosis, prognostication and treatment.

Breast:
1) Investigating biomarkers of pathogenesis, prognosis and epithelial stromal interactions in phyllodes tumours and other tumours showing stromal differentiation.
2) Investigating predictive and prognostic biomarkers in breast cancer.

Lung cancer:
Molecular biomarkers of therapeutic response.

Head and Neck pathology:
Studies relating to diagnosis and biomarkers of prognosis and response to therapy.

Genitourinary pathology:
1) Prostate cancer, including development of biomarkers of prognosis.
2) Renal cell carcinoma diagnosis.

Pancreatic cancer:
Collaborative studies of precursor lesions and development of biomarkers of prognosis.

Key Achievements

Publications:

  • Authors or co-authors of 64 peer reviewed journal articles published in 2015.
  • Including studies in some of the world's top ranked scientific journals including New England Journal of Medicine, Lancet Oncology, Nature, Nature Genetics, PNAS and Journal of Clinical Oncology.
  • These studies involved many national and international collaborators, eg researchers at the Melanoma Institute of Australia and the Garvan Institute of Medical Research.

Invited Conference Presentations:

  • Recognition of the importance of these studies through several oral presentation at key international and national scientific meetings.

Awards/Medals

Scolyer R, 2015 Winner Thomson Reuters Citation and Innovation Award for outstanding research team for research in BRAF-mutated melanoma. Co-winners Associate Professor Georgina Long, Professor Richard Kefford, Professor Grant McArthur. Award ceremony 23 June 2015.


Research Staff

  • Ms Kate Harvey, scientist working in molecular pathology and breast cancer
  • Ms Anne Holliday, scientist working in molecular pathology and breast cancer
  • Dr Jerry Wei, scientist working in molecular pathology and breast cancer
  • Ms Cassandra Kavanagh, scientist working in molecular pathology and breast cancer research
  • Dr Thang Tran, technical officer working on lung cancer research
  • Ms Susan Z. Wan, head and neck cancer biobanking officer
  • Ms Estella Sanchez-Guerrero, technical officer working on clinical validation of NGS in molecular genomics
  • Jia Qian, technical officer working on clinical validation of NGS in molecular genomics
  • Dr Ricardo Vilain, pathology fellow (MIA/Tissue Pathology)
  • Dr James Wilmott, research officer (MIA, USyd)
  • Ms Chitra deSilva, melanoma biobanking officer (MIA, USyd)

Higher Degree Students:

PhD:

  • Mun Hui, UNSW
  • Bruce Ashford, USyd
  • H Kakavand, USyd
  • T Nur Gurde, USyd
  • Raj Rai, Usyd,

Masters:

  • H Lee


Publications and Presentations

Publication Details:
  1. Rynkiewicz NK, Fedele CG, Chiam K, Gupta R, Kench JG, Severi G, Giles GG, McLean CA, Horvath LG, Mitchell CA. INPP4B, a negative regulator of PI3K/Akt signalling is expressed in prostate transit amplifying cells, and its loss of expression in prostate cancer predicts for recurrence and poor long term survival. Prostate 2015; 75: 92-102
  2. Matthews Y, McKenzie C, Byrne C, Kench JG. Intraductal tubulopapillary neoplasm of pancreas with associated invasive carcinoma, lymph node, rectal and hepatic metastases. Pathology 2015; 47: 169-71
  3. Waddell N, Pajic M, Patch A-M, Chang DK, Kassahn KS, Bailey P. Johns AL, Miller D, Nones K, Quek K, Quinn MCJ, ... Kench JG, ... Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM. Whole genome sequencing informs therapeutic selection for pancreatic cancer. Nature 2015; 518: 495-501
  4. Cheng R, Cooper A, Kench J, Watson G, Bye W, McNeil C, Shackel N. Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol 2015; 30: 657-66
  5. Chandrasegaram MD, Goldstein D, Simes J, Gebski V, Kench JG, Gill AJ, Samra JS, Merrett ND, Richardson AJ, Barbour AP and Collaborators. Systematic review and meta-analysis of R0 rates and margin assessment in pancreatic cancer. Br J Surgery 2015;102:1459-72
  6. Kitzing YX, Ng BH, Kitzing B, Waugh R, Kench JG, Strasser SI, McCormack S. Washout of hepatocellular carcinoma on portal venous phase of multidetector computed tomography in a pre-transplant population. J Med Imaging Radiat Oncol. 2015; 59:673-80
  7. Matsika A, Srinivasan B, Broomfield A, Day C, Fu J, Kiernan D, Mader S, Hopper JD, Kench JG, Samaratunga H. Stem cell markers in prostate cancer: an immunohistochemical study of ALDH1, SOX2 and EZH2. Pathology 2015; 47:622-8
  8. Luk PP, Selinger CI, Eviston TJ, Lum T, Yu B, O'Toole SA, Clark JR, Gupta R. Mammary analogue secretory carcinoma: an evaluation of its clinicopathological and genetic characteristics Pathology. 2015 Dec;47(7):659-66.
  9. Wilmott JS, Field MA, Johansson PA, Kakavand H, Shang P, De Paoli-Iseppi R, Vilain R, Pupo GM, Tembe V, Jakrot V, Shang CA, Cebon J, Shackleton M, Fitzgerald A, Thompson JF, Hayward NK, Mann GJ, Scolyer RA. Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology. 2015 Dec;47(7):683-93.
  10. Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, Colebatch AJ, De Paoli-Iseppi R, Li J, Lupat R, Semple T, Arnau GM, Fellowes A, Leonard JH, Hruby G, Mann GJ, Thompson JF, Cullinane C, Johnston M, Shackleton M, Sandhu S, Bowtell DDL, Johnstone RW, Fox SB, McArthur GA, Papenfuss AT, Scolyer RA, Gill AJ, Hicks RJ, Tothill RW. UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Res 2015;75:5228-34.
  11. Arafeh R, Qutob N, Emmanuel R, Keren-Paz A, Madore J, Elkahloun A, Wilmott JS, Gartner JJ, Di Pizio A, Winograd-Katz S, Sindiri S, Rotkopf R, Dutton-Regester K, Johansson P, Pritchard A, Waddell N, Hill VK, Lin JC, Hevroni Y, Rosenberg SA, Khan J, Ben-Dor S, Niv MY, Ulitsky I, Mann GJ, Scolyer RA, Hayward NK, Samuels Y. Recurrent inactivating RASA2 mutations in melanoma. Nat Genet 2015. Dec;47(12):1408-10.
  12. Chi MN, Guo ST, Wilmott JS, Guo XY, Yan XG, Wang CY, Liu XY, Jin L,1 Tseng H-Y, Croft A, Hondermarck H, Liu T, Scolyer RA, Jiang CC, Zhang XD. 'Inositol polyphosphate 4-phosphatase II functions as an oncogenic driver through activation of PI3K/SGK3 signaling in melanoma.' Oncotarget 2015. Nov 24;6(37):39891-907
  13. Shain AH, Garrido M, Botton T, Talevich E, Yeh I, Sanborn Z, Chung J, Wang NJ, Kakavand H, Mann GJ, Thompson JF, Wiesner T, Roy R, Olshen AB, Gagnon A, Gray JW, Huh N, Hur JS, Busam KJ, Scolyer RA, Cho RJ, Murali R, Bastian BC. 'Exome sequencing of desmoplastic melanoma reveals recurrent NFKBIE promoter mutations and diverse MAPK pathway activating mutations.' Nature Genet 2015. Oct;47(10):1194-9.
  14. Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziell RA, McKenzie CA, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, StGeorge G, Chinniah N, Halliday GM, Damian DL. 'A Phase 3 Randomized Trial of Nicotinamide for Skin Cancer Chemoprevention.' N Engl J Med 2015. Oct 22;373(17):1618-26.
  15. Gupta R, O'Connell R, Haynes A-M, Stricker PD, Barrett W, Turner JJ, Delprado W, Horvath LG, Kench JG. Extraprostatic extension of prostatic carcinoma: is its proximity to the surgical margin or Gleason score important? BJU International 2015; 116:343-50
  16. Sanborn Z, Chung J, Purdom E, Wang NJ, Kakaband H, Wilmott JS, Butler T, Thompson JF, Mann GJ, Haydu LE, Saw RP, Busam KJ, Lo R, Collisson EA, Hur JS, Spellman P, Cleaver JE, Gray JW, Huh N, Murali R, Scolyer RA, Bastian BC, Cho RJ. 'Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.' Proc Natl Acad Sci USA 2015;112(35):10995-1000.
  17. Henderson MA, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF. 'Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.' Lancet Oncol 2015. Sep;16(9):1049-60.
  18. Jayawardana K., Schramm S-J, Tembe V, Mueller S, Scolyer RA, Mann GJ, Yang YH. 'Identification, review and systematic cross-validation of microRNA prognostic signatures in metastatic melanoma.' J Invest Dermatol 2015. Sep 9. doi: 10.1038/jid.2015.355. [Epub ahead of print].
  19. Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JHJ, Scolyer RA, Siew K, Lomma C, Cooper A, Khattak MA, Meniawy TM, Long GV, Carlino MS, Millward M, Ziman M. 'Circulating tumor DNA to monitor 1 treatment response and detect acquired 2 resistance in patients with metastatic melanoma.' Oncotarget 2015;6:42008-18
  20. Prieto-Granada CN, Lezcano C, Scolyer RA, Mihm M, Piris A. 'Lethal Melanoma in Children: A Clinicopathological Study of 12 Cases.' Am J Surg Pathol 2015. Accepted for publication 26 September 2015.
  21. Kakavand H, Vilain RE, Wilmott JS, Burke H, Yearley JH, Thompson JF, Hersey P, Long GV, Scolyer RA. 'Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.' Mod Pathol 2015;28:1535-44.
  22. Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MMK, Thompson JF, Guminski A, Carlino MS, Scolyer RA, Kefford RF, Long GV. 'Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.' Cancer. 2015 Nov 1;121(21):3826-35.
  23. Kakavand H, Wilmott JS, Menzies AM, Vilain RE, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, Long GV, Scolyer RA. 'PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.' Clin Cancer Res 2015. Jul 15;21(14):3140-8.
  24. Kiyohara E, Donovan N, Takeshima L, Huang S, Wilmott JS, Scolyer RA, Jones P, Somers EB, O'Shannessy DJ, Hoon DS. 'Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications.' Cancer Microenviron. 2015;8:111-8
  25. Wilmott JS, Hersey P, Long GV, Scolyer RA. 'Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy?' Melanoma Manag 2015:2(1),15-19.
  26. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015 Jun 18;161(7):1681-96.
  27. Menzies AM, Yeh I, Botton T, Bastian BC, Scolyer RA, Long GV. 'Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.' Pigment Cell Melanoma Res. 2015;28:607-10
  28. Hardy TA, O'Brien B, Gerbis N, Barnett MH, Reddel SW, Brewer J, Herkes GK, Silberstein P, Garsia RJ, Watson JD, Gupta R, Parratt JD, Buckland ME.' Brain histopathology in three cases of Susac's syndrome: implications for lesion pathogenesis and treatment' J Neurol Neurosurg Psychiatry. 2015 May;86(5):582-4.
  29. Carlos G, Luk P, Scolyer RA, Guitera P. 'Reflectance confocal microscopy as a diagnostic aid in determined invasion in lentigo maligna clinical presentations.' Australas J Dermatol 2015 May 1;56:6.
  30. Vilain RE, McCarthy SW, Thompson JF, Scolyer RA. 'BAP1-inactivated spitzoid naevi.' Am J Surg Pathol. 2015 May;39(5):722.
  31. Theodosakis N, Meeth K, Micevic G, Scolyer RA, Long GV, Marzuka A, Stern D, Bosenberg M. 'BRAF inhibition decreases cellular glucose uptake in melanoma in association with reduction in cell volume.' Mol Cancer Ther. 2015 Jul;14(7):1680-92.
  32. Fogarty GB, Hong A, Dolven-Jacobsen K, Reisse CH, Burmeister B, Haydu LH, Dhillon H, Steel V, Shivalingam B, Drummond K, Vardy J, Nowak A, Hruby G, Scolyer RA, Mandel C, Thompson JF. 'First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality.' BMC Res Notes. 2015 May 8;8:192.
  33. Stark M, Klein K, Weide B, Haydu L, Pflugfelder A, Tang YH, Palmer J, Whiteman D, Scolyer RA, Mann GJ, Thompson JF, Long GV, Barbour A, Soyer HP, Garbe C, Herington A, Pollock P, Hayward N. 'The prognostic and predictive value of melanoma-related microRNAs using tissue and serum: a microRNA expression analysis.' EBioMedicine 2015. May 12;2(7):671-80.
  34. Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, Yu B, O'Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA. 'PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma Lung Cancer.' Lung Cancer 2015 Aug;89(2):181-8.
  35. Wilmott JS, Colebatch A, Kakavand H, Shang P, Carlino MS, Thompson JF, Long GV, Scolyer RA, Hersey P. 'Expression of the Class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma.' Mod Pathol. 2015;28:884-94
  36. Phan TG, Long GV, Scolyer RA. 'Multiple checkpoints on the long road towards cancer immunotherapy.' Immunol Cell Biol 2015 Apr;93(4):323-5.
  37. Carlino MS, Kwan V, Miller DK, Saunders CA, Yip D, Nagrial AM, Tomlinson J, Grimmond SM, Scolyer RA, Kefford RF, Biankin AV, Long GV. 'New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma.' J Clin Oncol. 2015 Apr 10;33(11):e52-6.
  38. Luk PP, Vilain R, Crainic O, McCarthy SW, Thompson JF, Scolyer RA. 'Punch biopsy of melanoma causing tumour cell implantation: another peril of utilising partial biopsies for melanocytic tumours.' Australas J Dermatol 2015 Apr 2;56, 227-231.
  39. MacKenzie Ross AD, Haydu LE, Quinn MJ, Saw RPM, Shannon KF, Spillane AJ, Stretch JR, Scolyer RA, Thompson JF. 'The association between excision margins and local recurrence in 11,290 thin (T1) primary cutaneous melanomas; a case control study.' Ann Surg Oncol 2016. Apr;23(4):1082-9.
  40. Gupta R, Balasubramanian D, Clark JR. Salivary gland lesions: recent advances and evolving concepts Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Jun;119(6):661-74.
  41. Aivazian K, Ebrahimi A, Low TH, Gao K, Clifford A, Shannon K, Clark JR, Gupta R.' Perineural invasion in oral squamous cell carcinoma: quantitative subcategorisation of perineural invasion and prognostication' J Surg Oncol. 2015 Mar;111(3):352-8.
  42. Holtkamp LHJ, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, Scolyer RA. Detailed pathological examination of completion node dissection specimens and outcome in melanoma patients with minimal (<0.1mm) sentinel lymph node metastases. Ann Surg Oncol 2015;22:2972-7
  43. Anforth R, Menzies AM, Byth K, Carlos G, Chou S, Sharma R, Scolyer RA, Kefford RF, Long GV, Fernandez-Penas P. 'Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.' J Am Acad Dermatol 2015;72:809-15
  44. Hardy KM, Strizzi L, Margaryan NV, Gupta K, Murphy GF, Scolyer RA, Hendrix MJ. Targeting Nodal in Conjunction with Dacarbazine Induces Synergistic Anticancer Effects in Metastatic Melanoma. Mol Cancer Res. 2015;13:670-80
  45. Wang J, Huang S, Marzese D, Hsu S, Kawas N, Chong K, Long GV, Menzies AM, Scolyer RA, Izraely S, Sagi-Assif O, Witz I, Kefford RF, Thompson J, Morton D, Hoon D. 'Epigenetic Changes of EGFR play an important role in BRAF inhibitor Resistant Cutaneous Melanomas.' J Invest Dermatol. 2015 Feb;135(2):532-41.
  46. Read RL, Haydu LE, Saw RPM, Quinn MJ, Shannon K, Spillane AJ, Stretch JR, Scolyer RA, Thompson, JF. 'In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy.' Ann Surg Oncol. 2015 Feb;22(2):475-81.
  47. Phan TG, Long GV, Scolyer RA. 'Multiple checkpoints on the long road towards cancer immunotherapy.' Immunol Cell Biol. 2015;93:323-5
  48. Anforth RM, Carlos GR, Scolyer RA, Chou S, Fernandez-Peñas P. 'Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma.' Melanoma Res. 2015 Feb;25(1):91-4.
  49. Billings S, Ko JS, Prieto VG, Elson P, Vilain RE, Pulitzer M, Scolyer RA, Reynolds JP, Piliang M, Ernstoff MS, Gastman B. 'Histologic pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of Stage III patients.' Modern Pathol 2016. Feb;29(2):122-30.
  50. Carlino MS, Fung C, Shahheydari H, Todd JR, Nagrial AM, Scolyer RA, Kefford RF, Long GV, Rizos, H. 'Pre-existing MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.' Clin Cancer Res 2015 Jan 1;21(1):98-105.
  51. Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, Long GV, Scolyer RA. 'PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients.' Clin Cancer Res. 2015;21:3140-8
  52. Madore J, Vilain R, Menzies AM, Kakavand H, Wilmott JS, Hyman J, Yearley JH, Kefford RF, Thompson JF, Long GV, Hersey P, Scolyer RA. 'PD-L1 expression in melanoma has prognostic significance but shows marked heterogeneity within and between patients- implications for anti-PD-1/PD-L1 clinical trials.' Pigment Cell Melanoma Res 2015 28(3):245-53
  53. Wilmott JS, Hersey P, Long GV, Scolyer RA. 'Synergistic effects of MAPK inhibition and immune checkpoint inhibitors in metastatic melanoma: what is the best combination and timing of these therapies?' Invited editorial. Melanoma Management 2015;2:15-19
  54. Micevic G, Muthusamy V, Scolyer RA, Bosenberg M. 'Multigene epigenetic signature is a prognostic marker in melanoma.' J Invest Dermatol 2015:135, S106-S113
  55. Johnson DB, Menzies AM, Zimmer L, Eroglud Z, Yea F, Zhaoa S, Rizos H, Sucker A, Scolyer RA, Gutzmerj R, Gogas H, Kefford RF, Thompson JT, Becker JC, Berking C, Egbertsn F, Loquai C, Goldinger S, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D. 'Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behavior, and phenotypic associations of resistance mechanisms.' Eur J Cancer 2015;51:2792-9
  56. Cooper, W.A., Preface-Molecular genetics of lung cancer. Translational Lung Cancer Research. 2015; 4:109 (Editorial).
  57. Kao, S.C., Fulham, M., Wong, K., Cooper, W., Sagong, J.O. Boyer, M. Pattison, S., Brahmbhatt, H., MacDiarmid, J., Reid, G., van Zandwijk, N. A significant metabolic and radiological response following a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. American Journal of Respiratory and Critical Care Medicine. 2015; 191:1467-1469.
  58. Williams M, Kirschner MB, Cheng YY, Hanh J, Weiss J, Mugridge N, Wright CM, Linton A, Kao SC, Edelman JB, Vallely MP, McCaughan BC, Cooper W, Klebe S, Lin RCY, Brahmbhatt H, MacDiarmid J, van Zandwijk N, Reid G. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget. 2015; 6:23480-95.
  59. Selinger, C., Cooper, W., Lum, T., McNeil, C., Morey, A., Waring, P., Amanuel, B., Millward, M., Peverall, J., Van Vliet, C., Christie, M., Tran, Y., Diakos, C., Pavlakis, N., Gill, A.J., O'Toole, S.A. Equivocal ALK FISH cases may benefit from ancillary ALK FISH probe testing. Histopathology 2015;67:654-63.
  60. Cooper, W.A., Tran, T., Madore, J., Selinger, C., Kohonen-Corish, M., Yip, P.Y., O'Toole, S.A., McCaughan, B.C., Horvath, L., Kao, S., Boyer, M., Scolyer, R.A. PD-L1 expression is a favourable prognostic factor in early stage NSCLC. Lung Cancer. 2015; 89:181-188.
  61. Wang, S., Yu, B., Ng, C.C., Mercorella, B., Selinger, C.I., O'Toole, S.A., Cooper, W.A. The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer. Translational Lung Cancer Research. 2015; 4:119-125.
  62. Luk, P.P., Yu, B., Ng, C.C., Mercorella, B., Selinger, C., Lum, T., Kao, S., O'Toole, S.A., Cooper, W.A. BRAF mutations in non-small cell lung cancer. Translational Lung Cancer Research. 2015; 4:142-148.
  63. Anderson S, Sasson SC, Lee FJ, Larsen S, Cooper W, Garsia R. Episodic fevers and vasodilatory shock mimicking urosepsis in a patient with HIV-associated Multicentric Castleman's Disease: a case report. BMC Infect Dis. 2015; 16: 53.
  64. Li BT, Lee A, O'Toole S, Cooper W, Yu B, Chaft JE, Arcila ME, Kris MG, Pavlakis N. HER2 insertion YVMA mutant lung cancer: long natural history and response to afatinib. Lung Cancer 2015; 90: 617-9

Book Chapters:
  1. Thompson JF, Scolyer RA, Kefford RF. 'Melanoma' in Oxford Textbook of Oncology. 3rd Ed. Oxford University Press, 2015 (in production).

Presentations:

Oral Presentations (Poster presentations not included)

International:

  1. Scolyer R, International Melanoma Pathology Study group workshop: Convenor and facilitator: Pathology terms, definitions and guidelines for AJCC staging, UCSF, San Francisco USA, 18 November 2015.
  2. Scolyer R, International Melanoma Pathology Study group workshop: Convenor and facilitator: Pathology terms, definitions and guidelines for AJCC staging, UCSF, San Francisco USA, 18 November 2015.
  3. Gupta R, World Congress on Larynx Cancer, Squamous lesions of the larynx, Cairns 2015

National:

  1. Kench JG. Invited Lecture: Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) Annual Scientific Meeting The 'new' ISUP modified Gleason grading system and ICCR datasets for prostate cancer, Sydney, July 2015
  2. O'Toole S, Invited lecture: Asia-Pacific International Academy of Pathology scientific meeting, The molecular pathology of breast cancer, June 2015.
  3. O'Toole S, Invited Lecture: Garvan Clinical Genomics Course, Somatic Cancer Mutation Testing, December 2015
  4. Scolyer R, Global Advances and Controversies in Skin Cancer, Update on Melanoma Pathology (speaker) and Interpreting the Difficult Skin Cancer (speaker and chair), Brisbane, Australia, October 2015.
  5. Scolyer R, Melanoma Round up: Melanoma Pathology Update for Clinicians, Melanoma Institute Australia, Sydney November 2015.
  6. Gupta R, Asia-Pacific International Academy of Pathology Scientific Meeting, Salivary gland tumours and fluorescent in situ hybridisation, Brisbane 2015
  7. Cooper WA. Sydney Catalyst Symposium, Mutation testing in lung cancer - bringing cancer genetic testing into clinical practice, Sydney 2015

Research Grants

GRANTING BODY AWARDEES PROJECT TITLE Total $$ Years
NHMRC Project Grant Clark S, Risbridger G, Bristow R, Pidsley R, Lawrence M, Kench J, Stricker P Epigenetic Changes in the Prostate Cancer Microenvironment  $      848,954 2016-18
NHMRC Project Grant Swarbrick A, Carroll J, Cowley M, O’Toole S  Mechanistic and functional analysis of the Id4 proto-oncogene in breast cancer   $      693,983 2016-18
NHMRC Program Grant Kefford RF, Thompson JF, Hersey P, Mann GJ, Scolyer RA, Hayward N, Long GV Molecular determinants of risk, progression and treatment response in melanoma.  $14,663,120 2016-20
CINSW Equipment Grant  Richardson D, Scolyer RA, Long GV, Halliday G, Murray M, Lee CS, Kumar N, Mason R, Payne R, Lay P Biacore T200 Molecular Interaction Analysis System for the Open Access, Multi-Disciplinary Sydney Cancer Research Core Facility  $      354,048 2015
NHMRC Project grant Damian D, Martin A, Halliday G, Eris J, Lowe PM, Fernandez Peñas P, McKenzie C, Scolyer RA, Chong A, Vardy J.  ONTRANS: Oral Nicotinamide for skin cancer chemoprevention after Transplant. NHMRC Project grant   $      624,824 2016-18
NHMRC Equipment Grant Richardson D, Scolyer RA, Murray M, Long GV, Slobedman B.  NanoString nCounter SPRINT Profiler System for Shared Use in the Open Access, Multi-User, Bosch Molecular Biology Facility.  $      199,000 2015

Contact details for department

Head of Department: Clinical Professor James Kench

Department/Unit: Tissue Pathology and Diagnostic Oncology
Address:
RPA Hospital
Missenden Road
Camperdown NSW 2050
Telephone: (02) 9515 7458
Facsimile: (02) 9515 8405
Web: http://www.slhd.nsw.gov.au/research/
Email: james.kench@sswahs.nsw.gov.au